[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Biogipuzkoa Health Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":132},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,38,78,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100642592","multimorbidity-and-polypharmacy-in-people-with-hiv-vs-the-general-population-in-the-basque-country-100642592",false,"NCT07621224","Multimorbidity and Polypharmacy in People With HIV vs. the General Population in the Basque Country","A Comparative Study on the Prevalence of Multimorbidity, Polypharmacy and Potentially Inappropriate Prescriptions Among the General Population and People Living With HIV in the Basque Country","Inclusion Criteria:\n\n* People with HIV aged 18 or over\n* Being monitored by the infectious diseases departments of the Araba, Cruces, Basurto and Donostia University Hospitals and the Galdakao-Usansolo Hospital, all part of Osakidetza.\n\nExclusion Criteria:\n\n\\- Being under 18 years of age",true,"ALL","18 Years",{"count":20,"type":21},12546,"ESTIMATED","OBSERVATIONAL","People living with HIV now have a life expectancy similar to that of the general population, thanks to major advances in antiretroviral treatment. As they live longer, many of them experience multiple health conditions at the same time and take several medications, often more than people without HIV. In our region, 6,273 people are currently receiving antiretroviral therapy. However, the new care pathway designed for patients with multiple chronic conditions in the Basque Country's public health system does not include people with HIV. At the same time, we lack local data on how common multimorbidity, polypharmacy, and potentially inappropriate prescribing are among this group. These gaps motivated our study. Our goal is to estimate how frequent these issues are among all people with HIV who receive care in the infectious disease departments of the hospitals in Araba, Basurto, Galdakao, Cruces, and Donostia, and to compare them with a similar group of people without HIV. To do this, we designed a cross-sectional study including the 6,273 people with HIV and a control group from the general population, selected to match them by age, sex, and health centre. By analysing data from electronic health records, we aim to determine whether people with HIV have higher rates of multimorbidity, polypharmacy, and inappropriate prescribing than the general population. The findings from both groups will help us update the care pathway and improve coordinated care for HIV-positive patients with multiple health conditions.",[25],"HIV (Human Immunodeficiency Virus)","NOT_YET_RECRUITING","2026-06-10",{"date":29,"type":30},"2026-06-12","ACTUAL",{"date":32,"type":21},"2026-09",{"date":34,"type":21},"2026-10",{"name":36,"class":37},"Biogipuzkoa Health Research Institute","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100624790","phase-1-evaluation-of-the-combined-therapy-of-eh-301-and-n-acetylcysteine-together-with-riluzole-in-amyotrophic-lateral-sclerosis-als-100624790","NCT07414212","Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)","A Phase II, Single-center, Randomized Double Blind, Placebo Controlled Study to Evaluate the Effect of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Ambulant Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)","NADALS-001-ALS","Inclusion Criteria:\n\n1. Patients diagnosed with ALS according to the Gold Coast criteria;\n2. Disease duration ≤ 18 months;\n3. Men and women aged 18 to 75 years;\n4. Total ALSFRS-R score ≥ 30 for all 12 categories;\n5. Forced vital capacity (FVC) ≥70%;\n6. The participant must receive treatment with Riluzole (50 mg twice daily) for ≥30 days prior to Day 1 (Visit 2) and is expected to remain on that dose until the final study visit.\n7. Willingness and ability of the patient to comply with the requirements of the protocol during the study;\n8. Sign written informed consent prior to any study-related procedure;\n9. Acceptance by women to use at least one highly effective method of contraception during the study 30 days prior to taking the nutraceutical and investigational drug and throughout the study. The following are considered highly effective contraceptive methods:\n\n   * Combined hormonal methods (oral, patches, injectables, or implants).\n   * Hormonal or copper intrauterine devices (IUDs).\n   * Previous surgical sterilization (bilateral tubal ligation).\n   * Total sexual abstinence when consistent with the patient's usual lifestyle.\n10. Acceptance by men included in the study of the use of condoms in combination with an effective contraceptive method used by their female partner of childbearing age during treatment.\n\nExclusion Criteria:\n\n1. Presence of other neurodegenerative diseases;\n2. Significant cognitive impairment and\u002For dementia;\n3. Any psychiatric illness that could interfere with the study;\n4. Use of dietary supplements with high doses of vitamin B3 in the 30 days prior to inclusion in the study;\n5. Severe heart disease;\n6. Moderate to severe lung disease, such as emphysema, stage III-IV COPD;\n7. Uncontrolled chronic asthma;\n8. Active cancer;\n9. Any metabolic, neoplastic, physically or mentally debilitating disease that could put the subject at risk or interfere with the study results;\n10. Genetically confirmed mitochondrial disease;\n11. Tracheostomized and\u002For gastrostomized patients;\n12. Participation in any clinical trial with an investigational product within 30 days or five half-lives of the previous agent, whichever is longer, prior to dosing;\n13. Any clinically significant laboratory abnormality that could directly affect compliance or safety;\n14. Allergy to NAC or any excipient, either in the investigational drug or in the EH301 nutraceutical;\n15. Patients with a short life expectancy in the investigator's judgment.\n16. \\[Women only\\] Pregnancy or breastfeeding for women of childbearing potential (i.e., \\\u003C2 years postmenopausal or not surgically sterile);\n17. The participant is unwilling to use highly effective contraception during the study.","75 Years",{"count":48,"type":21},90,"INTERVENTIONAL",[51,52],"PHASE1","PHASE2","This study is designed to evaluate whether a combination of N-acetylcysteine (NAC) and EH-301 can slow down or improve symptoms of amyotrophic lateral sclerosis (ALS). Researchers will assess changes in disease progression using the ALS Functional Rating Scale-Revised (ALSFRS-R), a standard tool for measuring daily functioning in people with ALS.\n\nThe main question is whether taking NAC together with EH-301 can prevent symptom worsening and possibly improve existing ALS symptoms.\n\nParticipants will be randomly assigned to receive either the active combination (NAC + EH-301) or matching placebos for 6 months. During this period, they will attend regular clinic visits for evaluations, tests, and safety monitoring.\n\nAfter completing the initial 6-month phase, all participants may choose to join a 6-month open-label extension, where everyone receives the active treatment regardless of their original group.",[55],"Amyotrophic Lateral Sclerosis",[55,57,58,59,60,61,62,63,64,65,66,67],"Acetylcysteine","EH301","ALSFRS-R","ALS","NAC","Hospital Universitario Donostia","Biogipuzkoa","Adolfo López de Munain","NADALS-001-ALS-2021","Open Label Extension","NADALS","RECRUITING","2026-02-10",{"date":71,"type":30},"2026-02-17",{"date":73,"type":30},"2025-11-25",{"date":75,"type":21},"2027-11-25",{"name":36,"class":37},1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":85,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":49,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":77},"100613730","study-of-the-influence-of-the-mediterranean-diet-on-the-quality-of-life-of-patients-with-endometriosis-100613730","NCT07270393","Study of the Influence of the Mediterranean Diet on the Quality of Life of Patients With Endometriosis.","Estudio de la Influencia de la Dieta mediterránea en la Calidad de Vida de Las Pacientes Con Endometriosis.","INCLUSION CRITERIA:\n\n* Female.\n* Age 18-45.\n* Premenopausal status.\n* Radiological diagnosis (by transvaginal ultrasound and\u002For MRI) and\u002For surgical diagnosis of endometriosis.\n* Follow-up in the Gynecology Department of OSI Donostia (at least 1 visit in the last year).\n* Clinical score of at least 3\u002F10 on the Numerical Scale in at least one symptom related to endometriosis).\n* Possibility of understanding Spanish.\n* Possibility of understanding the indicated dietary recommendations.\n* Acceptance of inclusion in clinical study, by signing informed consent.\n\nEXCLUSION CRITERIA:\n\n* Diagnosis of Eating Disorder.\n* Diagnosis of malabsorptive syndromes: Chron's disease, Ulcerative colitis, short bowel syndrome, gastric by-pass, irritable bowel.\n* Other concomitant diseases that produce CPD.\n* Autoimmune diseases.-\n* Metabolic diseases requiring follow-up of specific diets.\n* Diagnosed gluten intolerance.\n* Vegan diet.\n* Follow-up by a nutritionist.\n* Diagnosis of severe mental illness requiring treatment.\n* Pregnancy or current breastfeeding.\n* Active cancer process.\n* Personal history of gynecologic or digestive oncologic process.\n* Change of treatment or surgery during follow-up.\n* Surgery related to endometriosis or change of treatment in the 6 weeks prior to enrollment in the study.\n* Drug abuse. Opioid analgesia \\\u003C 3 months.","FEMALE","45 Years",{"count":88,"type":21},104,[90],"NA","The severities of chronic disease symptoms correlate with the levels of analytical parameters of inflammation. Studies have been published in which the Mediterranean diet has an anti-inflammatory phenomenon, decreasing inflammation parameters. This decrease correlates with an improvement in symptoms.\n\nEndometriosis is a chronic inflammatory disease and the influence of the Mediterranean diet on the decrease of inflammation parameters in women with endometriosis has been studied.\n\nThe studies carried out to assess whether this decrease in inflammatory parameters correlates with clinical improvement and quality of life in these patients have low\u002Fvery low scientific evidence (small sample size, no control group) and with different interventions (diets, restrictions and\u002For supplements), which prevent their analysis as a whole.\n\nTherefore, our hypothesis is that the Mediterranean diet, due to its anti-inflammatory effect, can improve the symptomatology and quality of life of patients with endometriosis.",[93],"Endometriosis",[93,95,96],"Mediterranean diet","Quality of life","2025-11-26",{"date":99,"type":30},"2025-12-08",{"date":101,"type":21},"2025-12-01",{"date":103,"type":21},"2026-12-01",{"name":36,"class":37},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":49,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},"100566843","exercise-during-chemotherapy-treatment-as-adjuvant-program-in-patients-with-lymphoma-edonola-study-100566843","NCT06660446","Exercise During Chemotherapy Treatment As Adjuvant Program in Patients with Lymphoma: EDONOLA Study.","Ejercicio Físico Durante El Tratamiento De Quimioterapia Como Programa Adyuvante En Pacientes Con Linfoma: Estudio EDONOLA","Inclusion Criteria:\n\n* Age: ≥18 years old.\n* Diagnosis of lymphoma with histological confirmation and requirement of systemic treatment including chemotherapy.\n* Time available (80 minutes, two days a week for 20 weeks) to carry out physical exercise sessions.\n* Have a mobile phone to be able to contact the person and download the physical activity level app.\n* Eastern Cooperative Oncology Group performance status (ECOG) ≤2.\n* Life expectancy \\>12 months.\n* Availability and desire to participate throughout the study period.\n\nExclusion Criteria:\n\n* Have a contraindication to moderate-high intensity exercise.\n* Other significant medical disorders: including psychiatric illnesses chronic or recurrent; intellectual disability, musculoskeletal problems, cardiac or pulmonary disorders that interfere with physical exercise; other malignant tumors in the last five years, with the exception of therapeutically controlled skin cancer; any other illness that may be seen affected or aggravated by physical exercise.\n* Have plans to be outside city more than two weeks.\n* People who are already physically active (that comply with the recommendations of WHO: \\> 150 minutes of exercise moderate\u002Fweekly, plus training force two days\u002Fweek).\n* Treatment based only with immunotherapy.\n* Central nervous system involvement due to lymphoma.\n* Have any important history that limit the capacity of the patient to participate in the study.",{"count":113,"type":21},180,[90],"In people diagnosed with lymphoma receiving immunochemotherapy treatment, a combined exercise intervention, as opposed to the general recommendations, will achieve: 1.Improve cardiorespiratory fitness, strength, psychological well-being and quality of life. \u002F\u002F2.Reduce fatigue\u002F\u002F3.Reduce frailty\n\nThere is an association between some biological biomarkers with physical capacity and frailty.",[117],"Lymphoma",[117,119,120,121,122],"Physical Exercise","Fatigue","Cardiorespiratory capacity","Life Quality","2025-02-18",{"date":125,"type":30},"2025-02-19",{"date":127,"type":30},"2024-10-08",{"date":129,"type":21},"2027-03-30",{"name":36,"class":37},3,""]